Search 

Johnson & Johnson (J&J) was founded in 1886 and is based in New Brunswick, NJ, with an Innovation Center in Cambridge, MA. The firm invests in a variety of fields within the life science sector, including medical devices. J&J’s medical device investments are highly varied in both size and structure; the structure may involve milestone payments, or may be an equity investment. J&J is interested in early stage medical device companies located globally.

JT Pharma, the Pharmaceutical Division of Japan Tobacco (Akros Pharma, US; Torii, Japan) has broad therapeutic interests with a focus on cutting edge, innovative science and orally active small molecule therapeutics in diabetes, lipid regulation, osteoporosis (small molecule anabolic agents), HIV, HBV, fibrosis, pain, autoimmune diseases, inflammation (RA and OA), urological diseases, allergy, and new drug discovery and development tools. Torii, the marketing division of JT Pharma Division, is interested in late stage, i.e. late Ph3, close to registration drugs for the Japanese market. Torii’s areas of interest are: renal diseases including CKD and complications from hemodialysis, dermatology, atopic dermatitis (preferably given orally), psoriasis, allergy, i.e. antigen-specific immunotherapy, asthma, and rhinitis. JT Pharma and Torii are looking for commercializable technologies or products for collaborative R&D deals or in- licensing deals. 
JT Pharma seeks partnering opportunities, i.e., research and/or development collaborations, contract research and licensing arrangements, to enhance its own internal R&D efforts. Also, Japan Tobacco’s marketing division, Torii Pharmaceuticals, seeks late-stage clinical opportunities for the Japanese Market.
JT Pharma has an interest in early-stage, novel small molecule therapeutics focusing on diabetes,lipid regulation, HIV, HBV, autoimmune disease, inflammation (RA, OA, asthma, allergy), fibrosis, osteoporosis, overactive bladder, and pain (non-CNS) as well as new drug discovery and development tools. Compounds must have composition of matter patents.

Torii Pharmaceuticals is seeking drugs in clinical trials for licensing and marketing in Japan with a focus on dermatology (eczema, atopic dermatitis, psoriasis, onychomycosis, ), allergy, and kidney diseases.

JT Pharma is dedicated to the discovery, development, and sales of novel human therapeutics. In addition to the North American facilities mentioned above, most of JT Pharma’s new drug discovery and development work is performed within its Central Pharmaceutical Research Institute, located in Osaka. They also have a molecular biology research laboratory in Yokohama and a toxicology research facility in Hadano, Japan.

JVC Investment Partners is a private investment firm that was founded in 2000 and is based in Chicago, Illinois. The firm focuses on investments in the healthcare industry. The investment size can vary greatly and is very flexible depending on each company’s needs. The firm provides venture capital and growth capital to healthcare companies. For early-stage investments, the firm targets companies that provide solutions for hospital acquired infections, medication errors, healthcare system operational efficiency enhancements and cost reductions, and chronic disease management, and it typically invests equity or convertible preferred equity in post series A rounds. For growth investments, the firm targets companies with compelling products and strong position in niche markets and with an EBITDA in excess of $2 million. The firm primarily invests in companies based in US.

Life Science Angels Inc was founded in 2004 and is based in Sunnyvale CA. The group makes early-stage equity investments in a wide range of life science companies. Life Science Angels invests primarily in California but is open to investing out of state provided a round is being syndicated with a local angel group. Life Science Angels does not rule out investing outside the USA but has yet to do so. The group invests as individuals and allocation sizes are therefore highly varied but are usually of about $2-$6, Life Science Angels usually invests in rounds seeking $3 million or less. The group is interested in syndicating rounds with other angel groups.

Life Science Nation (LSN) is the premier sourcing platform for market intelligence and prospect pipeline development in the life science arena. LSN enables life science professionals to generate a list of qualified global targets that are a fit for their company’s products, services, and fundraising efforts. The ability to generate these Global Target Lists (GTLs) makes life science professionals more effective and efficient. 

Lilly Asia Ventures is the venture capital arm of Eli Lilly that focuses on investments in the life sciences in Asia, particularly China. The firm was established in 2008 and is based in Shanghai, China. The firm is stage agnostic; investing in early, growth, and up to pre-IPO opportunities. The firm’s investment size is USD 5-20 million per company. The firm primarily invests in companies in China, but is open to companies across Asia-Pacific as long as there is some sort of China angle. The firm is actively seeking new investment opportunities.

Lilly Asia Ventures primarily focuses on therapeutics but is also interested in medical devices, diagnostics, animal health, and biotech other. The firm is most interested in products that will have a significant impact on medical care in China. For therapeutics, the firm seeks best-in-class or first-in-class products. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA. Historically, the firm invests in therapeutics for oncology, inflammatory diseases, and metabolic disorders.

Development-stage pharmaceutical company with a platform technology to deliver novel therapeutics to the urinary bladder lumen for the treatment of inflammatory bladder conditions such as overactive bladder and interstitial cystitis. Our portfolio includes prodcuts in pase-I and phase-II clinical trials in the United States and overseas, as well as pre-clinical programs. We also have one program designated as orphan. In addition to therapeutics, Lipella also develops diagnostic agents to be used in connection with medical imaging.

Longitude Capital is a private equity group founded in 2006 with offices in Menlo Park, California and Greenwich, Connecticut. The firm has $700 million in assets and has raised two funds, with the most recent fund closing at $385m in 2012. Longitude makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. Longitude Capital primarily invests in North America and the European Union but may also consider opportunities in the Middle East.

Lumira Capital is a Venture Capital firm that changed its name from MDS Capital In 2007 and have been investing in companies since 1989. The firm is based in Toronto will additional offices in Boston and Montreal. The firm currently manages 2 funds for a total of approximately $180 million in assets under management. The firm’s Lumira Capital II fund currently hold approximately $115 million in assets and is looking to invest in companies across North America. The firms Merck Lumira Biosciences fund formed via a partnership with Merck Serano, currently holds around $65 million in assets and is looking for early stage opportunities in companies located in or looking to move to Quebec. The firm typically makes initial investments ranging from $2-$5 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm plans to make 4-6 investments over the next 6-9 months.